Gilead downloads solid tumor program from Compugen for $60M upfront

Gilead Sciences is uploading $60 million to Compugen’s bank account plus hefty milestones down the road in exchange for the rights to a preclinical IL-18 binding protein program that includes a solid tumor asset.